Prevalence of Clinical Manifestations and Comorbidities of Coronavirus (COVID-19) Infection: A Meta-Analysis

Author(s): Farha Musharrat Noor, Md. Momin Islam

Abstract

Background: Since late December, 2019 an outbreak of coronavirus (COVID-19) emerged in China and continued to spread across the world. The main aim of this study was to investigate the prevalence of clinical characteristics and comorbidities of coronavirus (COVID-19) infected patients.

Methods: A meta-analysis was performed using three electronic databases PubMed, Science Direct and Google Scholar to assess clinical characteristics and comorbidities of COVID-19 confirmed cases from January 1, 2020 to April 2, 2020. The pooled prevalence rate (PR) and 95% confidence interval (CI) was calculated using a random effects model.

Result: Total 44 eligible studies were selected for analysis, including 7673 infected patients. Form the result it was found that the most prevalent clinical symptom was fever [PR: 84.49 %, 95 % CI: (81.87- 87.11)], following cough [PR: 56.39%, 95% CI (51.06 - 61.73)], fatigue [PR: 33.65%, 95% CI: (26.77 – 40.54)] , dyspnea [PR: 22.34%, 95% CI: (17.18 – 27.50)], sputum production [PR: 20.72%, 95% CI: (11.18 – 30.27)] and myalgia [PR: 16.26%, 95% CI: (12.93 – 19.59)]. The most prevalent comorbidity was hypertension [PR: 20.00%, 95% CI: (16.53 – 23.46)], following cardiovascular disease [PR: 11.19%, 95% CI: (6.76 – 15.62)], diabetes [PR: 9.78%, 95% CI: (8.02 – 11.55)], chronic liver disease [PR: 2.65%, 95% CI: (1.85 – 3.46)] and cerebrovascular disease [PR: 2.63%, 95% CI: (1.06 – 4.19)].

Conclusion: Fever, cough, fatigue were the most strongly predictive clinical symptoms and hypertension, cardiovascular disease, diabetes were the most prevalent comorbidities for COVID-19 infection.

© 2016-2022, Copyrights Fortune Journals. All Rights Reserved